Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq			5-day change	1st Jan Change
- ^USD	-.--%		+3.58%	+2.96%

21/18/21	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/18/21	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE

21/18/21	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/18/21	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
20/18/20	British shares falter as Fed, oil play Scrooge	RE
19/18/19	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
18/18/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
17/18/17	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
07/18/07	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
05/18/05	FTSE : falls as growth angst spreads	RE
05/18/05	Growth and trade nerves grind European shares down to two-week low	RE
05/18/05	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/18/05	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/18/21	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/18/21	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/20/13	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/20/04	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
07/19/07	Shire : Form 8.3 - Takeda Pharmaceutical	PU
07/19/07	Shire : Form 8.3 -	PU
07/19/07	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/19/08	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
07/19/07	Les affaires reprennent dans la pharmacie
21/18/21	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/18/18	Shire : plombé par le déclassement de Takeda
05/18/05	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Shire PLC Share Price Nasdaq

Stocks

SHPG

US82481R1068

Pharmaceuticals

Latest news : Shire PLC

Analysts' recommendations : Shire PLC

Press Releases : Shire PLC

News in other languages : Shire PLC

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE PLC	-.--%	+3.58%	-	-	0
ELI LILLY AND COMPANY	-0.13%	-6.44%	+60.34%	+112.06%	1,04700Cr
JOHNSON & JOHNSON	+0.85%	-0.81%	+51.29%	+63.13%	65TCr
ABBVIE INC.	-1.03%	-3.58%	+21.43%	+73.10%	45TCr
ROCHE HOLDING AG	-1.46%	-4.50%	+37.80%	+37.41%	35TCr
NOVARTIS AG	-0.72%	-2.89%	+22.32%	+36.62%	29TCr
ASTRAZENECA PLC	-1.19%	-2.21%	+1.53%	+10.79%	25TCr
AMGEN INC.	-1.05%	-1.57%	+50.30%	+66.55%	23TCr
NOVO NORDISK A/S	+0.08%	-1.78%	-17.64%	-54.36%	20TCr
GILEAD SCIENCES, INC.	-2.14%	-0.30%	+28.95%	+86.27%	18TCr
Average	-0.68%	-2.68%	+28.48%	+47.95%	40.66TCr
Weighted average by Cap.	-0.46%	-3.46%	+38.17%	+65.00%